How it works, simply
One molecule activates GLP-1, GIP and glucagon receptors: three hormone signals involved in appetite, blood sugar and energy use.
What the evidence tells us
Phase 3 programs study weight and glucose outcomes in specified populations. Lilly reports full publications as well as preliminary announcements; these should be distinguished when reading individual results. Trial results do not make retatrutide an FDA-approved medicine.
Phase 3 results have been reported, but it is not FDA approved. Triple agonist is the accurate term; GLP3 is an informal nickname, not a receptor name.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This guide does not establish a safe dose, interaction profile or long-term safety for self-use. Effects reported for one route or formulation may not apply to another.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates GIP, GLP-1 and glucagon receptors in a single molecule.
Sponsor or developer: Eli Lilly and Company
Studied or labeled topics: Obesity, Type 2 diabetes, Metabolic disease
2026-07-23: Sponsor-reported Phase 3 results in two additional trials; retatrutide remains investigational.
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- Lilly: retatrutide development and Phase 3 evidence overview ↗ · Sponsor · September 2026
- Lilly: TRIUMPH-2 and TRIUMPH-3 topline results ↗ · Sponsor · 2026-07-23
Readability updated October 10, 2026. Evidence review: October 10, 2026 (sponsor overview and status only). A wording update is not a new clinical review.